Effects of prostanoid EP agonists on mouse intraocular pressure

Investigative Ophthalmology & Visual Science
Tadashiro SaekiMakoto Araie

Abstract

To investigate the ocular hypotensive effect and change of outflow facilities by prostaglandin E2 (PGE2) and selective agonists of PGE2 receptor subtypes (EP1, -2, -3, -4) using C57BL/6 (wild-type [WT]) mice or FP, EP1, -2, and -3 receptor-deficient mice. IOP was measured with a microneedle, and IOP reduction was evaluated by the difference in IOP between the treated eye and the contralateral control eye. The time course and dose dependency of IOP reduction with PGE2 and the four selective EP receptor agonists were assessed. Aqueous humor outflow facility was measured by a two-level constant-pressure perfusion PGE2, ONO-AE1-259-01 (EP2 agonist), and ONO-AE1-329 (EP4 agonist) significantly reduced IOP in a dose-dependent manner, whereas ONO-DI-004 (EP1 agonist) and ONO-AE-248 (EP3 agonist) had no effect. Peak IOP reduction at 2 hours with 0.1% ONO-AE1-259-01 (EP2 agonist) and ONO-AE1-329 (EP4 agonist) were 21.1% +/- 4.8% and 17.5% +/- 2.9%, respectively (P < 0.01). IOP reduction with ONO-AE1-259-01 (EP2 agonist) was completely eliminated in EP2 knockout mice, but IOP reduction in other knockout mice was similar to that observed in WT mice. The effects of ONO-AE1-259-01 (EP2 agonist) and ONO-AE1-329 (EP4 agonist) on the outflow f...Continue Reading

Citations

Apr 18, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Yuko MaruyamaShigeru Kinoshita
Feb 20, 2013·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Robert L JonesJenny Wang
Oct 21, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·David F WoodwardCarol B Toris
Jan 10, 2016·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·He WuJian Wang
May 10, 2017·Expert Opinion on Pharmacotherapy·Mark S DikopfDeepak P Edward
Aug 8, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Megan E Cavet, Heleen H DeCory
Jul 11, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Masahiro FuwaJin-Zhong Zhang
Aug 30, 2019·Expert Opinion on Therapeutic Patents·Andrea Angeli, Claudiu T Supuran
Apr 14, 2016·Ophthalmic Genetics·Lance P Doucette, Michael A Walter
Jul 25, 2018·Scientific Reports·Reiko Yamagishi-KimuraMakoto Aihara
Apr 23, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Makoto Aihara
Jun 14, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Rei SakataMakoto Aihara
Jan 8, 2019·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Murray FingeretMarc Bloomenstein
Jul 7, 2021·Japanese Journal of Ophthalmology·Makoto Aihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.